Trigemina's Series A - II Round

Trigemina raised a round of funding on June 18, 2013.

Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina's lead product candidate, TI-001, is a patented new application of oxytocin…

Articles about Trigemina's Series A - II Round: